Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.

Elodie Blanchard , Olivier Lortholary (1, 2) , Karine Boukris-Sitbon , Marie Desnos-Ollivier (3, 4) , Françoise Dromer (3, 4) , Didier Guillemot (5) , Non Renseigné , Cornet M (6)

1 CEREDIH - Centre de Référence Déficits Immunitaires Héréditaires
2 Centre d'infectiologie Necker-Pasteur [CHU Necker]
3 Mycologie moléculaire
4 CNRMA - Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire
5 IP - Institut Pasteur [Paris]
6 TIMC-IMAG-TheREx - Thérapeutique Recombinante Expérimentale

Infections due to caspofungin-resistant Candida isolates in patients exposed to caspofungin therapy are increasing. We report here a nested case-control study which aimed at identifying factors associated with bloodstream infections caused by Candida spp. having reduced susceptibility to caspofungin (CRSC) in adults suffering from hematological malignancies. In univariate and multivariate analyses, infections with CRSC were associated with caspofungin exposure in the previous 30 days (odds ratio [OR] = 5.25; 95% confidence interval [95% CI], 1.68-16.35) and with an age of ≤ 65 years (OR = 3.27; 95% CI, 1.26-8.50).

Domaines: Mycologie

Elodie Blanchard, Olivier Lortholary, Karine Boukris-Sitbon, Marie Desnos-Ollivier, Françoise Dromer, et al.. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.. Antimicrobial Agents and Chemotherapy, 2011, 55 (11), pp.5358-61. ⟨10.1128/AAC.00690-11⟩. ⟨hal-00818510⟩